Tejara Capital Ltd Purchases New Stake in Integra LifeSciences Holdings Corporation $IART

Key Points

• Tejara Capital Ltd has made a new investment of approximately $1.21 million in Integra LifeSciences Holdings Corporation by acquiring 55,000 shares.
• Several institutional investors have significantly increased their stakes in Integra LifeSciences, with Assenagon Asset Management raising its position by 2,418.7% in the first quarter.
• Analysts have recently lowered their price targets for Integra LifeSciences, with JMP Securities setting a new target price of $25.00, down from $35.00, indicating a shift in market sentiment.

Tejara Capital Ltd bought a new position in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 55,000 shares of the life sciences company's stock, valued at approximately $1,209,000. Tejara Capital Ltd owned about 0.07% of Integra LifeSciences as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Sterling Capital Management LLC boosted its stake in shares of Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after buying an additional 1,931 shares during the last quarter. CWM LLC boosted its stake in shares of Integra LifeSciences by 413.8% in the first quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock worth $147,000 after buying an additional 5,367 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Integra LifeSciences in the first quarter worth about $223,000. NorthRock Partners LLC purchased a new stake in shares of Integra LifeSciences in the fourth quarter worth about $251,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Integra LifeSciences in the first quarter worth about $251,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on IART shares. JMP Securities lowered their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. JPMorgan Chase & Co. reduced their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Finally, Wells Fargo & Company reduced their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat, Integra LifeSciences currently has an average rating of "Reduce" and a consensus target price of $18.63.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock traded down $0.29 during mid-day trading on Wednesday, reaching $14.40. 339,237 shares of the stock traded hands, compared to its average volume of 1,024,220. The business has a 50-day moving average of $12.67 and a 200 day moving average of $16.64. Integra LifeSciences Holdings Corporation has a fifty-two week low of $11.06 and a fifty-two week high of $27.13. The stock has a market capitalization of $1.12 billion, a PE ratio of -2.20, a PEG ratio of 0.79 and a beta of 1.16. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The business had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same quarter in the prior year, the firm earned $0.63 earnings per share. The business's revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.